Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curaleaf HoldingsCURLF -1.18%72 3-Year EBITDA Growth Rate is 9.20% as of Mar. 2026, which is 38% below its 10-year median of 14.80. GuruFocus rates CURLF with a GF Score™ of 72/100 and a GF Value™ of $8.04 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 813 Drug Manufacturers companies, Curaleaf Holdings ranks better than 50.68% on this metric.
During the past 12 months, Curaleaf Holdings's average EBITDA Per Share Growth Rate was -3.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 9.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -0.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Curaleaf Holdings was 326.10% per year. The lowest was -5.50% per year. And the median was 14.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Curaleaf Holdings 3-Year EBITDA Growth Rate Related Terms
CURLF vs ZTS, UTHR: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curaleaf Holdings's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curaleaf Holdings 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curaleaf Holdings's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Curaleaf Holdings's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 9.20% mean?
Curaleaf Holdings (CURLF) has a 3-Year EBITDA Growth Rate of 9.20% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Curaleaf Holdings and its competitors. This is 38% below median its historical median of 14.80. According to the industry distribution chart, Curaleaf Holdings ranks #401 out of 813 companies in the Drug Manufacturers industry, placing it in the top 49.3%.
Is Curaleaf Holdings' 3-Year EBITDA Growth Rate too high?
Curaleaf Holdings' current 3-Year EBITDA Growth Rate of 9.20% is 38% below median its 10-year median of 14.80. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Curaleaf Holdings' value of 9.20% is 3.4% above this industry median. Based on the distribution chart, Curaleaf Holdings ranks #401 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Curaleaf Holdings has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Curaleaf Holdings' 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curaleaf Holdings ranks #401 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Curaleaf Holdings in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Curaleaf Holdings' value of 9.20% is 3.4% above this benchmark. While the company's 10-year median is 14.80 vs. the industry median of 8.90, Curaleaf Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Curaleaf Holdings's current 3-Year EBITDA Growth Rate of 9.20% is 3.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Curaleaf Holdings and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curaleaf Holdings's current 3-Year EBITDA Growth Rate is 9.20%, which is 38% below median its own 10-year median of 14.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curaleaf Holdings stock overvalued right now?
Based on GuruFocus' analysis, Curaleaf Holdings (CURLF) is currently considered Modestly Overvalued. The stock's GF Value™ is $8.04, compared to a current price of $9.24 — trading 14.9% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 9.20%, which is 38% below median its 10-year median of 14.80 and 3.4% above the Drug Manufacturers industry median of 8.90. Curaleaf Holdings' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Curaleaf Holdings (CURLF), the current 3-Year EBITDA Growth Rate is 9.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Curaleaf Holdings (CURLF) Overvalued in 2026?
Based on GuruFocus' analysis, Curaleaf Holdings stock appears to be overvalued.
The current stock price of $9.24 is trading 14.9% above its estimated GF Value™ of $8.04.
GuruFocus considers Curaleaf Holdings to be Modestly Overvalued.
Key valuation signals for CURLF:
3-Year EBITDA Growth Rate: 9.20% (38% below median its 10-year median of 14.80)
GF Value™: $8.04 vs. price of $9.24 (14.9% above fair value)
Industry Position: 3.4% above the Drug Manufacturers median (#401 of 813)
No single metric tells the full story. See the CURLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
72GF Score
Get the complete analysis for CURLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CURLF has been successfully added to your 
